8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Feb 26, 2026·SEC
Material company update
Nov 6, 2025·SEC
Puma Biotechnology, Inc.(PBYI)Earnings, Financials & Key Ratios
PBYI•NASDAQ
12.4× P/E·Price updated Jun 19, 2026
AboutPuma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.Show more
- Revenue$228M-0.9%
- EBITDA$48M+13.5%
- Net Income$31M+2.8%
- EPS (Diluted)0.61-1.6%
- Gross Margin74.53%+3.4%
- EBITDA Margin21.12%+14.6%
- Operating Margin16.33%+21.6%
- Net Margin13.62%+3.7%
- ROE27.97%-32.8%
PBYI Key Insights
Puma Biotechnology, Inc. (PBYI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 42.4%
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 18.3% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Trading near 52-week high
- ✓Efficient asset utilization: 1.1x turnover
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when PBYI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PBYI Price & Volume
Puma Biotechnology, Inc. (PBYI) stock price & volume — 10-year historical chart
Loading chart...
PBYI Growth Metrics
Puma Biotechnology, Inc. (PBYI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years0.29%
3 Years0.05%
TTM-2.38%
Profit CAGR
10 Years-
5 Years-
3 Years2396.29%
TTM-35.94%
EPS CAGR
10 Years-
5 Years-
3 Years210.89%
TTM-37.82%
Return on Capital
10 Years-34.53%
5 Years19.47%
3 Years26.06%
Last Year29.57%
PBYI Recent Earnings
Puma Biotechnology, Inc. (PBYI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.04+69.2%
$0.13
Rev
$45M+6.7%
$42M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.29+20.8%
$0.24
Rev
$60M-12.7%
$69M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.21+133.3%
$0.09
Rev
$54M-20.6%
$69M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.15+36.4%
$0.11
Rev
$52M+2.8%
$51M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.04vs $0.13+69.2% | $45Mvs $42M+6.7% |
| Q1 2026 | Feb 26, 2026 | $0.29vs $0.24+20.8% | $60Mvs $69M-12.7% |
| Q4 2025 | Nov 6, 2025 | $0.21vs $0.09+133.3% | $54Mvs $69M-20.6% |
| Q3 2025 | Aug 7, 2025 | $0.15vs $0.11+36.4% | $52Mvs $51M+2.8% |
Based on last 12 quarters of dataView full earnings history →
PBYI Peer Comparison
Puma Biotechnology, Inc. (PBYI) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 TGTX | 8.15B | 53.22 | 19.21 | 87.32% | 65.95% | 87.36% | 0.40 | |
 PTCT | 6.55B | 78.98 | 10.15 | 114.51% | -22.58% | |||
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 EXEL | 13.19B | 51.91 | 18.67 | 6.98% | 35.08% | 40.21% | 0.08 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 PFE | 143.46B | 25.22 | 18.54 | -1.65% | 11.83% | 8.34% | 0.78 | |
 AZN | 271.19B | 174.93 | 26.75 | 8.63% | 17.19% | 22.24% | 0.61 |
Compare PBYI vs Peers
Puma Biotechnology, Inc. (PBYI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PBYI Income Statement
Puma Biotechnology, Inc. (PBYI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 27.7M | 251M | 272.26M | 225.11M | 253.16M | 228.03M | 235.64M | 230.47M | 228.37M | 227.18M |
Revenue Growth % | - | 806.14% | 8.47% | -17.32% | 12.46% | -9.92% | 3.34% | -2.19% | -0.91% | -2.38% |
Cost of Goods Sold | 5.6M | 34.6M | 36.81M | 39.37M | 63.7M | 55.09M | 62.68M | 64.4M | 58.16M | 58.02M |
COGS % of Revenue | 20.22% | 13.78% | 13.52% | 17.49% | 25.16% | 24.16% | 26.6% | 27.94% | 25.47% | - |
Gross Profit | 22.1M▲ 0% | 216.4M▲ 879.2% | 235.44M▲ 8.8% | 185.74M▼ 21.1% | 189.45M▲ 2.0% | 172.94M▼ 8.7% | 172.96M▲ 0.0% | 166.06M▼ 4.0% | 170.21M▲ 2.5% | 169.15M▲ 0% |
Gross Margin % | 79.78% | 86.22% | 86.48% | 82.51% | 74.84% | 75.84% | 73.4% | 72.06% | 74.53% | 74.46% |
Gross Profit Growth % | 2023.41% | 879.19% | 8.8% | -21.11% | 2% | -8.72% | 0.01% | -3.98% | 2.5% | - |
Operating Expenses | 314.5M | 311.1M | 311.04M | 216.14M | 188.16M | 149.22M | 140.31M | 135.1M | 132.91M | 139.67M |
OpEx % of Revenue | 1135.38% | 123.94% | 114.24% | 96.01% | 74.33% | 65.44% | 59.55% | 58.62% | 58.2% | - |
Selling, General & Admin | 106.7M | 146.2M | 141.64M | 118.49M | 116.29M | 89.98M | 89.31M | 80.16M | 71.21M | 72.24M |
SG&A % of Revenue | 385.2% | 58.25% | 52.02% | 52.64% | 45.94% | 39.46% | 37.9% | 34.78% | 31.18% | - |
Research & Development | 207.8M | 164.9M | 132.85M | 97.65M | 71.87M | 52.24M | 50.38M | 54.94M | 62.07M | 68M |
R&D % of Revenue | 750.18% | 65.7% | 48.8% | 43.38% | 28.39% | 22.91% | 21.38% | 23.84% | 27.18% | - |
Other Operating Expenses | -100K | 0 | 36.55M | 0 | 0 | 7M | 625K | 0 | -362K | -575K |
Operating Income | -292.4M▲ 0% | -94.7M▲ 67.6% | -75.59M▲ 20.2% | -30.4M▲ 59.8% | 1.29M▲ 104.2% | 23.72M▲ 1738.8% | 32.64M▲ 37.6% | 30.97M▼ 5.1% | 37.3M▲ 20.5% | 29.49M▲ 0% |
Operating Margin % | -1055.6% | -37.73% | -27.77% | -13.51% | 0.51% | 10.4% | 13.85% | 13.44% | 16.33% | 12.98% |
Operating Income Growth % | -5.71% | 67.61% | 20.17% | 59.78% | 104.24% | 1738.76% | 37.61% | -5.13% | 20.45% | - |
EBITDA | -289.59M | -87.32M | -67.52M | -20.37M | 12.6M | 33.56M | 44.16M | 42.49M | 48.24M | 40.13M |
EBITDA Margin % | -1045.45% | -34.79% | -24.8% | -9.05% | 4.98% | 14.72% | 18.74% | 18.44% | 21.12% | 17.66% |
EBITDA Growth % | -5.13% | 69.85% | 22.67% | 69.83% | 161.83% | 166.45% | 31.58% | -3.78% | 13.53% | -17.55% |
D&A (Non-Cash Add-back) | 2.81M | 7.38M | 8.08M | 10.03M | 11.3M | 9.84M | 11.52M | 11.52M | 10.94M | 10.64M |
EBIT | -291.24M | -102.59M | -60.52M | -45.74M | -15.99M | 12.05M | 36M | 36.55M | 42.4M | 33.13M |
Net Interest Income | 536K | -9.19M | -12.17M | -13.56M | -12.65M | -10.78M | -10.72M | -7.73M | -2.54M | -1.2M |
Interest Income | 1.26M | 1.8M | 2.8M | 489K | 160K | 813K | 2.6M | 4.72M | 4.08M | 3.98M |
Interest Expense | 720K | 11M | 15M | 14.05M | 12.81M | 11.59M | 13.33M | 12.45M | 6.62M | 5.18M |
Other Income/Expense | 435K | -18.92M | 53K | -29.39M | -30.09M | -23.26M | -9.97M | -6.87M | -1.52M | -399K |
Pretax Income | -292M▲ 0% | -113.6M▲ 61.1% | -75.54M▲ 33.5% | -59.79M▲ 20.9% | -28.8M▲ 51.8% | 457K▲ 101.6% | 22.67M▲ 4861.5% | 24.1M▲ 6.3% | 35.78M▲ 48.5% | 29.09M▲ 0% |
Pretax Margin % | -1054.15% | -45.26% | -27.75% | -26.56% | -11.38% | 0.2% | 9.62% | 10.46% | 15.67% | 12.8% |
Income Tax | -2.21M | -7.92M | 53K | 207K | 324K | 455K | 1.08M | -6.18M | 4.67M | 4.7M |
Effective Tax Rate % | 0.76% | 6.97% | -0.07% | -0.35% | -1.12% | 99.56% | 4.78% | -25.63% | 13.05% | 16.17% |
Net Income | -292M▲ 0% | -113.6M▲ 61.1% | -75.59M▲ 33.5% | -59.99M▲ 20.6% | -29.13M▲ 51.5% | 2K▲ 100.0% | 21.59M▲ 1079450.0% | 30.28M▲ 40.2% | 31.11M▲ 2.8% | 24.38M▲ 0% |
Net Margin % | -1054.15% | -45.26% | -27.77% | -26.65% | -11.51% | 0% | 9.16% | 13.14% | 13.62% | 10.73% |
Net Income Growth % | -5.8% | 61.1% | 33.46% | 20.64% | 51.45% | 100.01% | 1079450% | 40.23% | 2.75% | -35.94% |
Net Income (Continuing) | -291.95M | -113.58M | -75.59M | -59.99M | -29.13M | 2K | 21.59M | 30.28M | 31.11M | 24.38M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -7.86▲ 0% | -2.99▲ 62.0% | -2.13▲ 28.8% | -1.52▲ 28.6% | -0.72▲ 52.6% | 0.02▲ 102.8% | 0.45▲ 2116.7% | 0.62▲ 37.8% | 0.61▼ 1.6% | 0.48▲ 0% |
EPS Growth % | 5.19% | 61.96% | 28.76% | 28.64% | 52.63% | 102.82% | 2116.75% | 37.78% | -1.61% | -37.82% |
EPS (Basic) | -7.86 | -2.99 | -2.13 | -1.52 | -0.72 | 0.02 | 0.46 | 0.62 | 0.62 | - |
Diluted Shares Outstanding | 37.17M | 37.94M | 38.77M | 39.58M | 40.64M | 44.93M | 47.55M | 49.1M | 50.65M | 50.85M |
Basic Shares Outstanding | 37.17M | 37.94M | 38.77M | 39.58M | 40.64M | 44.67M | 47.13M | 48.65M | 50.01M | 50.85M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
PBYI Balance Sheet
Puma Biotechnology, Inc. (PBYI) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 106.39M | 203M | 166.3M | 146.14M | 140.02M | 134.28M | 156.19M | 147.66M | 162.69M | 142.26M |
Cash & Short-Term Investments | 81.7M | 108.4M | 111.64M | 93.39M | 82.11M | 81.07M | 95.94M | 100.97M | 97.53M | 101.6M |
Cash Only | 81.7M | 108.4M | 60.04M | 85.29M | 63.13M | 76.2M | 84.58M | 69.22M | 29.64M | 36.2M |
Short-Term Investments | 0 | 0 | 51.61M | 8.1M | 18.98M | 4.87M | 11.35M | 31.75M | 67.89M | 65.4M |
Accounts Receivable | 9.67M | 21.95M | 28.9M | 25.54M | 32.53M | 42.27M | 48.49M | 32.01M | 53.65M | 26.33M |
Days Sales Outstanding | 127.42 | 31.92 | 38.74 | 41.42 | 46.9 | 67.66 | 75.11 | 50.7 | 85.75 | 56.02 |
Inventory | 2.03M | 2.63M | 3.17M | 3.45M | 7.11M | 4.53M | 7.08M | 8.72M | 5.51M | 0 |
Days Inventory Outstanding | 132.25 | 27.69 | 31.43 | 32.02 | 40.73 | 29.99 | 41.23 | 49.44 | 34.61 | 37.09 |
Other Current Assets | 11.69M | 3.85M | 11.74M | 11.75M | 11.43M | 1.95M | 260K | 3.7M | 5.99M | 14.33M |
Total Non-Current Assets | 59.13M | 56.12M | 68.61M | 98.08M | 86.56M | 87.78M | 74.34M | 65.67M | 53.62M | 50.44M |
Property, Plant & Equipment | 4.47M | 3.96M | 21.83M | 18.89M | 15.77M | 12.51M | 8.65M | 5.09M | 5.56M | 0 |
Fixed Asset Turnover | 6.20x | 63.34x | 12.47x | 11.92x | 16.05x | 18.23x | 27.25x | 45.24x | 41.07x | 59.67x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 48.35M | 44.41M | 40.46M | 74.14M | 66.13M | 70.61M | 60.87M | 51.13M | 41.39M | 38.96M |
Long-Term Investments | 4.32M | 2K | 0 | 0 | 0 | 0 | 2.09M | 0 | 0 | 0 |
Other Non-Current Assets | 6.31M | 6.01M | 6.32M | 5.06M | 4.67M | 4.66M | 2.73M | 2.38M | 2.83M | 11.48M |
Total Assets | 165.53M▲ 0% | 259.12M▲ 56.5% | 234.91M▼ 9.3% | 244.22M▲ 4.0% | 226.59M▼ 7.2% | 222.06M▼ 2.0% | 230.53M▲ 3.8% | 213.33M▼ 7.5% | 216.3M▲ 1.4% | 192.7M▲ 0% |
Asset Turnover | 0.17x | 0.97x | 1.16x | 0.92x | 1.12x | 1.03x | 1.02x | 1.08x | 1.06x | 1.13x |
Asset Growth % | -34.52% | 56.55% | -9.35% | 3.97% | -7.22% | -2% | 3.81% | -7.46% | 1.39% | -13.39% |
Total Current Liabilities | 58.34M | 67.11M | 90.84M | 114.25M | 109.59M | 77.48M | 99.38M | 96.11M | 81.25M | 59.74M |
Accounts Payable | 27.69M | 20.68M | 19.18M | 12.08M | 11.17M | 6.44M | 6.89M | 5.51M | 5.06M | 8.17M |
Days Payables Outstanding | 1.8K | 218.2 | 190.19 | 111.95 | 64.03 | 42.67 | 40.11 | 31.22 | 31.73 | 39.37 |
Short-Term Debt | 0 | 0 | 0 | 14.29M | 0 | 0 | 34M | 45.33M | 23.84M | 11.41M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 27.85M | 40.29M | 5.76M | 15.09M | 11.22M | 13.34M | 43.42M | 39.73M | 52.36M | 40.16M |
Current Ratio | 1.82x | 3.02x | 1.83x | 1.28x | 1.28x | 1.73x | 1.57x | 1.54x | 2.00x | 2.38x |
Quick Ratio | 1.79x | 2.99x | 1.80x | 1.25x | 1.21x | 1.67x | 1.50x | 1.45x | 1.93x | 2.38x |
Cash Conversion Cycle | -1.55K | -158.59 | -120.02 | -38.51 | 23.6 | 54.98 | 76.22 | 68.92 | 88.63 | 53.74 |
Total Non-Current Liabilities | 53.88M | 157.7M | 126.61M | 135.92M | 119.44M | 122.97M | 77.7M | 25.1M | 4.71M | 4.55M |
Long-Term Debt | 48.48M | 151.89M | 94.96M | 84.03M | 97.09M | 98.31M | 65.66M | 21.72M | 4.71M | 4.55M |
Capital Lease Obligations | 0 | 0 | 22.64M | 19.55M | 15.97M | 11.83M | 7.03M | 1.49M | 0 | 9.57M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5.41M | 5.82M | 9M | 32.34M | 6.38M | 12.83M | 5.01M | 1.88M | 0 | 0 |
Total Liabilities | 112.22M | 224.82M | 217.44M | 250.17M | 229.03M | 200.45M | 177.09M | 121.21M | 85.96M | 64.28M |
Total Debt | 48.48M | 151.89M | 120.23M | 120.95M | 116.64M | 114.28M | 111.49M | 74.08M | 28.55M | 15.95M |
Net Debt | -33.22M | 43.49M | 60.19M | 35.66M | 53.51M | 38.08M | 26.91M | 4.86M | -1.09M | -20.25M |
Debt / Equity | 0.91x | 4.43x | 6.88x | - | - | 5.29x | 2.09x | 0.80x | 0.22x | 0.12x |
Debt / EBITDA | - | - | - | - | 9.26x | 3.41x | 2.52x | 1.74x | 0.59x | 0.40x |
Net Debt / EBITDA | - | - | - | - | 4.25x | 1.13x | 0.61x | 0.11x | -0.02x | -0.50x |
Interest Coverage | -404.49x | -9.33x | -4.03x | -3.26x | -1.25x | 1.04x | 2.70x | 2.94x | 6.40x | 6.40x |
Total Equity | 53.3M▲ 0% | 34.31M▼ 35.6% | 17.46M▼ 49.1% | -5.95M▼ 134.1% | -2.45M▲ 58.9% | 21.61M▲ 983.4% | 53.44M▲ 147.3% | 92.13M▲ 72.4% | 130.34M▲ 41.5% | 128.42M▲ 0% |
Equity Growth % | -74.59% | -35.64% | -49.1% | -134.08% | 58.9% | 983.4% | 147.33% | 72.38% | 41.48% | 251.74% |
Book Value per Share | 1.43 | 0.90 | 0.45 | -0.15 | -0.06 | 0.48 | 1.12 | 1.88 | 2.57 | 2.53 |
Total Shareholders' Equity | 53.3M | 34.31M | 17.46M | -5.95M | -2.45M | 21.61M | 53.44M | 92.13M | 130.34M | 128.42M |
Common Stock | 4K | 4K | 4K | 4K | 4K | 5K | 5K | 5K | 5K | 5K |
Retained Earnings | -1.09B | -1.2B | -1.28B | -1.34B | -1.37B | -1.37B | -1.35B | -1.31B | -1.28B | -1.29B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -449K | -12K | 62K | 0 | -2K | 0 | -4K | 6K | 36K | -31K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PBYI Cash Flow Statement
Puma Biotechnology, Inc. (PBYI) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -172.5M | -24.1M | 22.38M | 800K | 20.65M | -15.83M | 27.01M | 38.92M | 41.8M | 53.61M |
Operating CF Margin % | -622.74% | -9.6% | 8.22% | 0.36% | 8.16% | -6.94% | 11.46% | 16.89% | 18.3% | - |
Operating CF Growth % | -21.74% | 86.03% | 192.85% | -96.42% | 2481.25% | -176.64% | 270.65% | 44.09% | 7.41% | 1578.14% |
Net Income | -291.95M | -113.58M | -75.59M | -59.99M | -29.13M | 2K | 21.59M | 30.28M | 31.11M | 24.38M |
Depreciation & Amortization | 2.81M | 7.38M | 8.08M | 10.03M | 11.3M | 9.84M | 11.52M | 11.52M | 10.94M | 10.73M |
Stock-Based Compensation | 108.73M | 86.94M | 57.33M | 36.58M | 32.63M | 11.83M | 10.25M | 8.24M | 6.94M | 6.81M |
Deferred Taxes | 0 | 5K | 0 | 0 | 0 | 0 | 0 | -7.08M | 3.25M | 0 |
Other Non-Cash Items | -30K | 289K | 9.28M | 1.03M | 7.15M | 7M | 1.51M | -519K | -358K | 2.68M |
Working Capital Changes | 7.94M | -5.14M | 23.28M | 13.16M | -1.31M | -44.5M | -17.85M | -3.54M | -10.08M | 9M |
Change in Receivables | -9.67M | -11.1M | -8.12M | 2.35M | -5.98M | -7.82M | -8.37M | 16.34M | -21.28M | -582K |
Change in Inventory | -2.03M | -596K | -545K | -284K | -3.65M | 2.58M | -2.55M | -1.64M | 3.21M | 58K |
Change in Payables | 7.66M | -7.01M | -1.53M | -7.11M | -902K | -4.73M | 449K | -1.38M | -453K | 2.14M |
Cash from Investing | -15.4M | -57.6M | 5.16M | 23.3M | -10.88M | 7.1M | -19.13M | -20.44M | -36.19M | -35.24M |
Capital Expenditures | -50.43M | -609K | -306K | -20.05M | 0 | -7M | -140K | -56K | -71K | -10K |
CapEx % of Revenue | 182.06% | 0.24% | 0.11% | 8.91% | - | 3.07% | 0.06% | 0.02% | 0.03% | 0% |
Acquisitions | 36K | 193K | 0 | 20M | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -15.01M | -170K | 0 | -20.1M | 0 | 0 | -12.5M | 0 | 0 | 0 |
Cash from Financing | 75.1M | 108.4M | -67.07M | 100K | -31.93M | 12.22M | 0 | -33.85M | -45.2M | -45.17M |
Debt Issued (Net) | 50M | 105M | -55M | 0 | -1.5M | 0 | 0 | -33.33M | -44.44M | -44.44M |
Equity Issued (Net) | 0 | 0 | 0 | 68K | 0 | 12.5M | 0 | 150K | 130K | 130K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 25.11M | 3.45M | -12.07M | 32K | -30.43M | -277K | 0 | -666K | -888K | -856K |
Net Change in Cash | -112.8M▲ 0% | 26.72M▲ 123.7% | -39.53M▼ 247.9% | 24.24M▲ 161.3% | -22.16M▼ 191.4% | 3.5M▲ 115.8% | 7.88M▲ 125.3% | -15.37M▼ 294.9% | -39.58M▼ 157.6% | -26.84M▲ 0% |
Free Cash Flow | -222.93M▲ 0% | -24.71M▲ 88.9% | 22.07M▲ 189.3% | -19.25M▼ 187.2% | 20.65M▲ 207.3% | -22.83M▼ 210.5% | 14.37M▲ 162.9% | 38.86M▲ 170.5% | 41.73M▲ 7.4% | 53.6M▲ 0% |
FCF Margin % | -804.81% | -9.84% | 8.11% | -8.55% | 8.16% | -10.01% | 6.1% | 16.86% | 18.27% | 23.59% |
FCF Growth % | -49.63% | 88.92% | 189.32% | -187.2% | 207.3% | -210.54% | 162.95% | 170.46% | 7.38% | 71.96% |
FCF per Share | -6.00 | -0.65 | 0.57 | -0.49 | 0.51 | -0.51 | 0.30 | 0.79 | 0.82 | 1.05 |
FCF Conversion (FCF/Net Income) | 0.59x | 0.21x | -0.30x | -0.01x | -0.71x | -7913.50x | 1.25x | 1.29x | 1.34x | 2.20x |
Interest Paid | 0 | 8.05M | 11.74M | 9.7M | 10.34M | 10.32M | 11.63M | 10.77M | 0 | 2.6M |
Taxes Paid | 0 | 17K | 53K | 207K | 324K | 384K | 737K | 1.22M | 0 | 1.18M |
PBYI Key Ratios
Puma Biotechnology, Inc. (PBYI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -221.97% | -259.34% | -292.05% | -1042.3% | - | 0.02% | 57.54% | 41.6% | 27.97% | 20.37% |
Return on Invested Capital (ROIC) | -1239.79% | -145.14% | -72.95% | -42.47% | 2.4% | 32.13% | 34.96% | 26.19% | 24.73% | 20.13% |
Gross Margin | 79.78% | 86.22% | 86.48% | 82.51% | 74.84% | 75.84% | 73.4% | 72.06% | 74.53% | 74.46% |
Net Margin | -1054.15% | -45.26% | -27.77% | -26.65% | -11.51% | 0% | 9.16% | 13.14% | 13.62% | 10.73% |
Debt / Equity | 0.91x | 4.43x | 6.88x | - | - | 5.29x | 2.09x | 0.80x | 0.22x | 0.12x |
Interest Coverage | -404.49x | -9.33x | -4.03x | -3.26x | -1.25x | 1.04x | 2.70x | 2.94x | 6.40x | 6.40x |
FCF Conversion | 0.59x | 0.21x | -0.30x | -0.01x | -0.71x | -7913.50x | 1.25x | 1.29x | 1.34x | 2.20x |
Revenue Growth | - | 806.14% | 8.47% | -17.32% | 12.46% | -9.92% | 3.34% | -2.19% | -0.91% | -2.38% |
Related:PBYI Dividend History·PBYI Revenue History·PBYI Price History·PBYI P/E History·PBYI Financial Ratios·PBYI Institutional Holders
PBYI SEC Filings & Documents
Puma Biotechnology, Inc. (PBYI) SEC filings — annual & quarterly reports (10-K, 10-Q)
PBYI Frequently Asked Questions
Puma Biotechnology, Inc. (PBYI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Puma Biotechnology, Inc. (PBYI) reported $227.2M in revenue for fiscal year 2025.
Puma Biotechnology, Inc. (PBYI) saw revenue decline by 0.9% over the past year.
Yes, Puma Biotechnology, Inc. (PBYI) is profitable, generating $24.4M in net income for fiscal year 2025 (13.6% net margin).
Dividend & Returns
Puma Biotechnology, Inc. (PBYI) has a return on equity (ROE) of 28.0%. This is excellent, indicating efficient use of shareholder capital.
Puma Biotechnology, Inc. (PBYI) generated $53.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.